JP2013523748A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523748A5
JP2013523748A5 JP2013502716A JP2013502716A JP2013523748A5 JP 2013523748 A5 JP2013523748 A5 JP 2013523748A5 JP 2013502716 A JP2013502716 A JP 2013502716A JP 2013502716 A JP2013502716 A JP 2013502716A JP 2013523748 A5 JP2013523748 A5 JP 2013523748A5
Authority
JP
Japan
Prior art keywords
group
alkyl
formulation
solvent system
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013502716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/030271 external-priority patent/WO2011123416A1/en
Publication of JP2013523748A publication Critical patent/JP2013523748A/ja
Publication of JP2013523748A5 publication Critical patent/JP2013523748A5/ja
Pending legal-status Critical Current

Links

JP2013502716A 2010-03-29 2011-03-29 注射用薬物送達製剤 Pending JP2013523748A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31871710P 2010-03-29 2010-03-29
US61/318,717 2010-03-29
PCT/US2011/030271 WO2011123416A1 (en) 2010-03-29 2011-03-29 Injectable drug delivery formulation

Publications (2)

Publication Number Publication Date
JP2013523748A JP2013523748A (ja) 2013-06-17
JP2013523748A5 true JP2013523748A5 (enExample) 2014-05-15

Family

ID=44246149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013502716A Pending JP2013523748A (ja) 2010-03-29 2011-03-29 注射用薬物送達製剤

Country Status (5)

Country Link
US (1) US8697105B2 (enExample)
EP (1) EP2552969A1 (enExample)
JP (1) JP2013523748A (enExample)
CA (1) CA2794958A1 (enExample)
WO (1) WO2011123416A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794958A1 (en) 2010-03-29 2011-10-06 Surmodics, Inc. Injectable drug delivery formulation
CA2858161C (en) * 2011-12-05 2020-03-10 Incept, Llc Medical organogel processes and compositions
JP2017538751A (ja) * 2014-12-19 2017-12-28 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 流動性止血組成物
CN114449998A (zh) * 2019-08-29 2022-05-06 保罗·道格拉斯·戈德弗林 口服递送剂型水凝胶、其制备方法和使用方法
CN112569179B (zh) * 2020-12-25 2022-12-27 上海交通大学医学院附属第九人民医院 一种可注射水凝胶体系及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DK89592D0 (da) * 1992-07-07 1992-07-07 Helle Broendsted Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf
US6884842B2 (en) * 1997-10-14 2005-04-26 Alnis Biosciences, Inc. Molecular compounds having complementary surfaces to targets
IL155866A0 (en) * 2003-05-12 2003-12-23 Yissum Res Dev Co Responsive polymeric system
CN101309709A (zh) * 2005-09-21 2008-11-19 苏尔莫迪克斯公司 包含天然生物可降解的多糖的涂层和物品
US20070260054A1 (en) 2006-03-15 2007-11-08 Surmodics, Inc. Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof
EP2037977A2 (en) 2006-06-28 2009-03-25 SurModics, Inc. Active agent eluting matrices with particulates
US20080089923A1 (en) 2006-09-29 2008-04-17 Burkstrand Michael J Biodegradable ocular implants and methods for treating ocular conditions
US20080220047A1 (en) * 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2009005718A1 (en) 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles having sustained release characteristics, methods and uses
EP2185637B1 (en) * 2007-09-19 2013-04-03 SurModics, Inc. Biocompatible foams, systems, and methods
CA2722425A1 (en) 2008-04-28 2009-11-05 Surmodics, Inc. Poly-.alpha.(1-4)glucopyranose-based matrices with hydrazide crosslinking
WO2010047799A1 (en) 2008-10-22 2010-04-29 Surmodics, Inc. Swellable biodegradable polymeric matrices and methods
US20100302403A1 (en) 2009-06-02 2010-12-02 Raytheon Company Generating Images With Different Fields Of View
CA2763522A1 (en) 2009-06-02 2010-12-09 Surmodics, Inc. Silane-functionalized hydrophobic .alpha.(1.fwdarw.-4)glucopyranose polymers and polymeric matrices for implantation or injection
CA2794958A1 (en) 2010-03-29 2011-10-06 Surmodics, Inc. Injectable drug delivery formulation

Similar Documents

Publication Publication Date Title
Jiang et al. Progress on ocular siRNA gene‐silencing therapy and drug delivery systems
JP6700348B2 (ja) 持続型薬物送達インプラント
AU2015257651B2 (en) Compounds for treating ophthalmic diseases and disorders
RU2664686C2 (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
US20240285518A1 (en) Ocular hydrogel tyrosine kinase inhibitor implants
US20100098772A1 (en) Drug delivery systems and methods for treating neovascularization
JP2007535552A5 (enExample)
WO2010004594A1 (en) Ophthalmic compositions for treating pathologies of the posterior segment of the eye
CN109072241A (zh) 具有改善的玻璃体内半衰期的组合物及其用途
JP2013501579A5 (enExample)
RU2690841C1 (ru) Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества
JP2013523748A5 (enExample)
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
US8697105B2 (en) Injectable drug delivery formulation
US20250009755A1 (en) Compositions and methods for the treatment of ocular diseases and injuries
US20190275001A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
HK40067669A (en) Ocular hydrogel tyrosine kinase inhibitor implants
HK40092417A (zh) 用於治疗眼科疾病和障碍的化合物